Australian Clinical Labs Ltd (AU:ACL)
ASX:ACL
Want to see AU:ACL full AI Analyst Report?
Top Page
Australian Clinical Labs Ltd
(Sydney:ACL)
Select Model
Select Model
Rating:59Neutral
Price Target:
AU$2.00
▼(-4.31% Downside)
Action:DowngradedDate:02/17/26
Overall score is held back primarily by weak technicals (price below all major moving averages with negative MACD), partially offset by solid cash flow generation and an attractive valuation (moderate P/E and high dividend yield). Financial leverage remains a key risk despite decent ROE and improving gross margin.
Positive Factors
Free Cash Flow Strength
Consistent FCF growth (up 8.67%) and strong cash conversion (OCF/NI 0.84, FCF/NI 0.95) provide durable internal funding. That supports capital expenditure, working-capital needs, debt servicing and strategic initiatives without relying solely on external capital.
Negative Factors
High Leverage
A debt-to-equity ratio of 1.69 implies significant leverage, increasing interest expense and refinancing risk. Over 2-6 months this constrains strategic flexibility, raises vulnerability to reimbursement cuts or volume declines, and limits capacity for opportunistic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Consistent FCF growth (up 8.67%) and strong cash conversion (OCF/NI 0.84, FCF/NI 0.95) provide durable internal funding. That supports capital expenditure, working-capital needs, debt servicing and strategic initiatives without relying solely on external capital.
Read all positive factors
Australian Clinical Labs Ltd (ACL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$360.33M
Dividend Yield4.6%
Average Volume (3M)867.30K
Price to Earnings (P/E)23.9
Beta (1Y)0.94
Revenue Growth1.12%
EPS Growth-12.02%
CountryAU
Employees4,900
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)0.15
Shares Outstanding187,672,410
10 Day Avg. Volume799,589
30 Day Avg. Volume867,296
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)3.09
Price to Sales (P/S)0.71
P/FCF Ratio3.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$2.33Price Target Upside11.24% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)0.16
Revenue Forecast (FY)AU$736.59M
Australian Clinical Labs Ltd Business Overview & Revenue Model
Company Description
Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier...
How the Company Makes Money
ACL primarily makes money by delivering pathology (diagnostic testing) services and earning fees for processing patient specimens and producing test results. Key revenue streams include: (1) Community/outpatient pathology: tests ordered by GPs and...
Australian Clinical Labs Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
58
Neutral
Cash Flow
72
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 733.52M | 741.27M | 689.73M | 692.10M | 989.30M | 641.31M |
| Gross Profit | 209.96M | 270.86M | 138.45M | 566.02M | 781.71M | 521.73M |
| EBITDA | 133.59M | 81.36M | 169.65M | 184.93M | 372.75M | 196.67M |
| Net Income | 26.31M | 32.43M | 23.93M | 35.90M | 178.24M | 60.37M |
Balance Sheet | ||||||
| Total Assets | 562.50M | 574.84M | 593.06M | 578.91M | 628.04M | 474.70M |
| Cash, Cash Equivalents and Short-Term Investments | 23.14M | 22.12M | 26.84M | 20.59M | 27.51M | 36.28M |
| Total Debt | 453.61M | 290.38M | 308.90M | 316.32M | 262.38M | 294.26M |
| Total Liabilities | 411.46M | 402.86M | 415.30M | 406.24M | 395.49M | 392.79M |
| Stockholders Equity | 150.57M | 171.35M | 177.53M | 172.42M | 232.44M | 81.90M |
Cash Flow | ||||||
| Free Cash Flow | 156.69M | 174.39M | 153.09M | 136.75M | 262.83M | 144.36M |
| Operating Cash Flow | 164.57M | 182.80M | 159.59M | 143.68M | 284.09M | 153.86M |
| Investing Cash Flow | -8.32M | -8.89M | -7.25M | -12.18M | -72.04M | -6.08M |
| Financing Cash Flow | -154.65M | -178.74M | -146.14M | -137.88M | -220.91M | -147.37M |
Australian Clinical Labs Ltd Technical Analysis
Neutral
2.09
Price Trends
2.14
Negative
2.41
Negative
2.49
Negative
Market Momentum
-0.02
Negative
51.92
Neutral
56.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ACL, the sentiment is Neutral. The current price of 2.09 is above the 20-day moving average (MA) of 2.03, below the 50-day MA of 2.14, and below the 200-day MA of 2.49, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.92 is Neutral, neither overbought nor oversold. The STOCH value of 56.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:ACL.
Australian Clinical Labs Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$9.87B | 10.64 | 6.39% | 4.69% | 13.14% | -2.73% | |
59 Neutral | AU$360.33M | 23.92 | 16.35% | 4.60% | 1.12% | -12.02% | |
55 Neutral | AU$846.38M | 26.42 | 2.05% | 2.65% | 56.28% | 55.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$363.08M | -5.40 | -29.48% | ― | -12.15% | -2285.99% |
* Healthcare Sector Average
AU:ACL
Australian Clinical Labs Ltd
1.89
-1.10
-36.91%
AU:HLS
Healius Limited
0.48
-0.68
-58.48%
AU:SHL
Sonic Healthcare Limited
19.28
-5.68
-22.76%
AU:IDX
Integral Diagnostics Ltd.
2.23
-0.07
-2.87%
Australian Clinical Labs Ltd Corporate Events
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
May 5, 2026
Australian Clinical Labs has continued its on-market share buy-back program, confirming a cumulative repurchase of 8,168,983 ordinary fully paid shares prior to the latest reporting date. The company reported that it bought back a further 50,000 s...
Macquarie Group Ceases to Be Substantial Holder in Australian Clinical Labs
May 4, 2026
Macquarie Group Limited and a wide range of its controlled entities have notified Australian Clinical Labs that they have ceased to be a substantial holder in the company. The filing, made under Australian substantial holding rules, indicates a ch...
Australian Clinical Labs Continues On-Market Share Buy-Back Program
Apr 30, 2026
Australian Clinical Labs has continued its on-market share buy-back program, targeting its ordinary fully paid ACL shares as part of an ongoing capital management strategy. The latest update shows that 50,000 shares were repurchased on the previou...
ACL Subsidiary SunDoctors Hit by Contained Cyber Incident via External IT Provider
Apr 30, 2026
Australian Clinical Labs has disclosed that an external IT service provider used by its SunDoctors subsidiary suffered a cyber incident, allowing unauthorised access to a limited part of SunDoctors’ systems and briefly disrupting its practic...
Australian Clinical Labs Cancels Shares After On-Market Buy-Back
Apr 23, 2026
Australian Clinical Labs has cancelled 232,345 fully paid ordinary shares following the completion of an on-market share buy-back. The reduction in issued capital marginally increases the ownership percentage of remaining shareholders and reflects...
Australian Clinical Labs Faces Class Action Over 2022 Medlab Cyberattack
Apr 20, 2026
Australian Clinical Labs has disclosed that it is facing a representative class action in the Supreme Court of Victoria, brought on behalf of customers of Medlab Pathology and/or ACL whose personal information was compromised in a February 2022 cy...
United Super exits substantial holder position in Australian Clinical Labs
Apr 17, 2026
Australian Clinical Labs has disclosed that institutional investor United Super Pty Ltd has ceased to be a substantial holder in the company as of 13 April 2026. The change was formalised in a statutory notice lodged under the Corporations Act, in...
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
Apr 17, 2026
Australian Clinical Labs has provided an updated notification on its ongoing on-market share buy-back program, confirming that a total of 8,118,983 ordinary fully paid shares had been repurchased before the previous trading day. On the previous da...
Australian Clinical Labs Cancels Shares Under On-Market Buy-Back
Apr 16, 2026
Australian Clinical Labs has cancelled 253,085 ordinary fully paid shares as part of an on-market buy-back, effective 15 April 2026. The move marginally reduces the company’s issued capital and may improve capital management metrics, with a ...
Australian Clinical Labs Continues On‑Market Share Buy‑Back Program
Apr 16, 2026
Australian Clinical Labs has reported an update on its on‑market share buy‑back program, confirming that it is continuing to repurchase its ordinary fully paid shares on the ASX. The company disclosed that a total of 8,083,340 shares h...
Australian Clinical Labs Continues Daily On‑Market Share Buy-Back
Apr 15, 2026
Australian Clinical Labs Ltd, a listed provider of pathology and diagnostic testing services, trades on the ASX under the code ACL with ordinary fully paid shares. The company operates in the healthcare sector and its equity is held by a broad bas...
Australian Clinical Labs Reports Ongoing On-Market Share Buy-Back Activity
Apr 14, 2026
Australian Clinical Labs has provided a daily update on its on-market share buy-back program for its ordinary fully paid shares, reporting that it repurchased 132,581 shares on the previous trading day. This takes the cumulative number of shares b...
Australian Clinical Labs Cancels 539,443 Shares in On-Market Buy-Back
Apr 14, 2026
Australian Clinical Labs has cancelled 539,443 ordinary fully paid shares as part of an on-market share buy-back, with the cessation of these securities effective 10 April 2026. The reduction in issued capital may marginally enhance earnings per s...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Apr 13, 2026
Australian Clinical Labs Ltd has an on-market share buy-back program in place for its ordinary fully paid shares traded under the ASX code ACL. The company has been steadily repurchasing stock as part of this capital management initiative.The late...
Australian Clinical Labs Presses Ahead With On‑Market Share Buy-Back
Apr 13, 2026
Australian Clinical Labs has continued its on‑market share buy-back program, focusing on repurchasing its ordinary fully paid shares listed under the ASX code ACL. The latest daily notification shows the company is actively executing the buy...
Australian Clinical Labs Cancels Shares Following On-Market Buy-Back
Apr 10, 2026
Australian Clinical Labs Limited has reported a reduction in its issued capital following the cancellation of 402,868 ordinary fully paid shares. The securities ceased on April 2, 2026, as a result of an on-market share buy-back, reflecting the co...
Australian Clinical Labs Continues Daily On‑Market Share Buy‑Back
Apr 10, 2026
Australian Clinical Labs has been conducting an on-market share buy-back of its fully paid ordinary shares, as disclosed in an updated notification to the ASX dated 10 April 2026. The company reported that a total of 7,699,160 shares had been repu...
Australian Clinical Labs Updates Market on Ongoing On-Market Share Buy-Back
Apr 9, 2026
Australian Clinical Labs has disclosed an on-market share buy-back of its ordinary fully paid securities, identified by the ASX code ACL, as part of an ongoing capital management initiative. The company reported that a total of 7,505,380 shares ha...
Macquarie Group Ceases to Be Substantial Holder in Australian Clinical Labs
Apr 8, 2026
Macquarie Group Limited and its controlled entities have lodged a notice indicating they have ceased to be a substantial shareholder in Australian Clinical Labs Ltd. The change in substantial holding, formalised on 8 April 2026, signals a withdraw...
Australian Clinical Labs Continues On-Market Share Buy-Back Program
Apr 7, 2026
Australian Clinical Labs Ltd has continued its on-market share buy-back program for its ordinary fully paid shares, ACL, as disclosed in an updated Appendix 3C filing. The latest daily notification dated 8 April 2026 reports that a total of 7,505,...
Australian Clinical Labs announces departure of director Grant Jeffery
Apr 7, 2026
Australian Clinical Labs has announced that director Grant Jeffery ceased to be a member of its board effective 7 April 2026, with a final director’s interest notice lodged to the ASX. The filing confirms that Jeffery held no relevant intere...
Australian Clinical Labs Announces Resignation of Non-Executive Director
Apr 6, 2026
Australian Clinical Labs has announced the immediate resignation of non-executive director Grant Jeffery, who joined the board on 1 February 2025. The company has expressed its appreciation for Jeffery’s contributions during his tenure, and ...
Australian Clinical Labs Reports Ongoing On-Market Share Buy-Back Activity
Apr 1, 2026
Australian Clinical Labs has reported ongoing activity under its on-market share buy-back program for its ordinary fully paid shares listed on the ASX. The company disclosed that a total of 7,094,110 shares had been repurchased before the previous...
Australian Clinical Labs Cancels Shares Following On-Market Buy-Back
Apr 1, 2026
Australian Clinical Labs has cancelled 201,534 ordinary fully paid shares following completion of an on-market share buy-back, as disclosed in its latest capital notification. The reduction in issued capital marginally increases ownership percenta...
Australian Clinical Labs Continues Daily On‑Market Share Buy‑Back
Apr 1, 2026
Australian Clinical Labs has continued its on‑market share buy‑back program, reporting that a total of 6,894,110 ordinary fully paid shares had been repurchased before the most recent trading day. The company disclosed that a further 2...
Australian Clinical Labs Reports Progress on On‑Market Share Buy‑Back
Mar 29, 2026
Australian Clinical Labs Limited has provided an updated notification to the ASX on its ongoing on‑market share buy‑back of ordinary fully paid shares. The latest daily update, dated 30 March 2026, reports that the company has repurcha...
Australian Clinical Labs Updates Daily On-Market Share Buy-Back
Mar 26, 2026
Australian Clinical Labs Limited, a listed Australian pathology and medical diagnostics provider trading under the ticker ACL, offers laboratory testing services to healthcare providers and patients across the country. Its operations focus on deli...
Australian Clinical Labs Extends On-Market Share Buy-Back
Mar 25, 2026
Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a further tranche of its ordinary fully paid shares as part of a previously announced capital management initiative. The daily notification shows that the co...
Australian Clinical Labs Cuts Share Count Through On-Market Buy-Back
Mar 25, 2026
Australian Clinical Labs Ltd, a key player in Australia’s pathology and diagnostic testing industry, provides laboratory services that support medical practitioners and healthcare systems nationwide. Its operations centre on processing clini...
Australian Clinical Labs Updates Market on Ongoing Share Buy‑Back Activity
Mar 24, 2026
Australian Clinical Labs has provided an updated notification to the ASX on the progress of its on‑market share buy‑back program for its ordinary fully paid shares. The company reported that a total of 6,489,708 shares had been repurch...
Australian Clinical Labs Reports Daily Progress on On‑Market Share Buy‑Back
Mar 23, 2026
Australian Clinical Labs has updated the market on its ongoing on‑market share buy‑back of ordinary fully paid shares. The company reported that it had repurchased a cumulative 6,388,208 shares prior to the latest trading day and bough...
Australian Clinical Labs Cancels Shares Following On-Market Buy-Back
Mar 23, 2026
Australian Clinical Labs has cancelled 573,748 fully paid ordinary shares following an on-market share buy-back, as disclosed in its latest capital notification to the exchange. The move reduces the company’s issued capital base and may incr...
Australian Clinical Labs Updates Progress of On-Market Share Buy-Back
Mar 22, 2026
Australian Clinical Labs has continued its on-market share buy-back program, repurchasing a total of 6,138,208 ordinary fully paid shares prior to the latest reporting date. The company bought back a further 250,000 shares on the previous trading ...
Australian Clinical Labs Continues On-Market Share Buy-Back Program
Mar 19, 2026
Australian Clinical Labs has an on-market share buy-back in place for its ordinary fully paid shares on the ASX, as part of a capital management program first notified in October 2025. The latest daily update shows that the company repurchased 81,...
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
Mar 17, 2026
Australian Clinical Labs has provided an updated notification to the ASX on its ongoing on-market share buy-back of ordinary fully paid shares. The latest daily report, dated 18 March 2026, confirms that the company repurchased 80,063 shares in th...
Australian Clinical Labs Updates Market on Ongoing Share Buy‑Back Activity
Mar 16, 2026
Australian Clinical Labs has been conducting an on‑market share buy‑back of its ordinary fully paid shares, as part of a previously announced capital management program first notified in October 2025. The company reported that, as of t...
Australian Clinical Labs Updates Market on Progress of On‑Market Share Buy-Back
Mar 11, 2026
Australian Clinical Labs Limited has updated the market on its ongoing on‑market share buy-back program for its ordinary fully paid shares listed under the ASX code ACL. The company reported that a total of 5,690,543 shares had been repurcha...
Australian Clinical Labs Cancels Over 1 Million Shares in On‑Market Buy‑Back
Mar 11, 2026
Australian Clinical Labs has cancelled 1,012,269 ordinary fully paid shares following an on‑market buy‑back completed on 9 March 2026. The reduction in issued capital through the buy‑back may enhance earnings per share and signal...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Mar 10, 2026
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back of ordinary fully paid shares. The company reported that, as of 11 March 2026, it has repurchased a cumulative 5,607,148 sh...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Mar 9, 2026
Australian Clinical Labs Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code ACL. The company reported that, as of the latest notification dated 10 March 2026, it had ...
Australian Clinical Labs Reports Ongoing On‑Market Share Buy‑Back Activity
Mar 5, 2026
Australian Clinical Labs Ltd, a pathology and diagnostic services provider listed on the ASX, is continuing to execute its on-market share buy-back program for its ordinary fully paid shares. The company operates in the Australian healthcare secto...
Australian Clinical Labs Service Rights Lapse Reduces Potential Equity Pool
Mar 4, 2026
Australian Clinical Labs has reported a change in its issued capital following the lapse of 125,145 service rights, identified under the ASX security code ACLAD. These rights ceased on 9 January 2026 after the conditions attached to them were not ...
Australian Clinical Labs Updates Market on Progress of On-Market Share Buy-Back
Mar 3, 2026
Australian Clinical Labs Ltd has provided an updated notification to the ASX regarding its ongoing on-market share buy-back program for its ordinary fully paid shares. The company reported that a total of 5,113,904 securities had been repurchased ...
Australian Clinical Labs Updates Daily On-Market Share Buy-Back Activity
Mar 2, 2026
Australian Clinical Labs has disclosed an update to its on-market share buy-back program for its ordinary fully paid shares listed on the ASX under ticker ACL. The filing notes that, as of the latest reporting date, the company continues to execut...
Australian Clinical Labs Updates Progress on On‑Market Share Buy‑Back
Mar 1, 2026
Australian Clinical Labs has provided an updated notification on its on‑market share buy‑back program for its fully paid ordinary shares. The announcement records that, as of the latest daily update, the company has bought back 100,000...
Australian Clinical Labs Cancels 900,000 Shares in On‑Market Buy‑Back
Feb 27, 2026
Australian Clinical Labs Limited has cancelled 900,000 fully paid ordinary shares as part of an on‑market buy‑back, effective 24 February 2026. The reduction in issued capital signals an active capital management program that may enhan...
Australian Clinical Labs Reports Daily Progress of On-Market Share Buy-Back
Feb 26, 2026
Australian Clinical Labs has provided an updated notification on its on-market share buy-back program for its fully paid ordinary shares. The company reported that, as of the latest daily update, it had repurchased a cumulative total of 4,829,786 ...
Citi Group Entities Exit Substantial Holder Position in Australian Clinical Labs
Feb 25, 2026
Citigroup Global Markets Australia Pty Limited and related Citi group entities have ceased to be substantial holders in Australian Clinical Labs, after reducing their relevant interest in the company’s ordinary fully paid shares. The change ...
Australian Clinical Labs Updates Progress of On‑Market Share Buy‑Back
Feb 25, 2026
Australian Clinical Labs Limited has provided an update on its on‑market share buy‑back program for its ordinary fully paid shares. The company reported that a total of 4,670,516 shares had been repurchased before the previous trading ...
Australian Clinical Labs Continues On‑Market Share Buy‑Back Program
Feb 23, 2026
Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a total of 4,470,516 ordinary fully paid shares prior to the latest trading day under the existing mandate first notified in October 2025. The co...
Australian Clinical Labs Updates Market on Ongoing Share Buy-Back
Feb 22, 2026
Australian Clinical Labs has continued its on-market share buy-back program, updating the market with a daily notification to the ASX. The company reported that it has repurchased a total of 4,270,516 ordinary fully paid shares prior to the latest...
Australian Clinical Labs Director Sarah Butler Acquires Indirect Shareholding
Feb 20, 2026
Australian Clinical Labs has disclosed a change in director Sarah Butler’s relevant interests, with Butler acquiring an indirect stake in the company through a trust structure. The transaction signals increased alignment between the director...
Australian Clinical Labs Lifts Total On‑Market Buy‑Back to Over 4 Million Shares
Feb 19, 2026
Australian Clinical Labs has continued its on‑market share buy‑back program, repurchasing a further 200,000 ordinary fully paid shares on 19 February 2026. This lifts the total number of shares bought back under the program to 4,070,51...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.